Trials / Recruiting
RecruitingNCT06677892
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Prospective, Non-interventional Study to Describe The Use of Maribavir and Its Effectiveness in Patients With Post-transplant Cytomegalovirus Infection/Disease in Line With Belgian Reimbursement Conditions (The MARIBEL Study)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (estimated)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant. The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria. During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This is non-interventional study. |
Timeline
- Start date
- 2025-02-24
- Primary completion
- 2026-08-01
- Completion
- 2026-09-01
- First posted
- 2024-11-07
- Last updated
- 2025-09-09
Locations
9 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06677892. Inclusion in this directory is not an endorsement.